33 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
and development (R&D) expenses were $57.5 million, compared to $36.6 million for the same period in 2023. These increases were primarily driven by expenses
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
expense
Research and development, or R&D, expenses consist primarily of costs incurred for current or planned investigations undertaken … and share-based compensation expense for the various R&D departments, costs associated with clinical trial activities undertaken by contract research
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
for sustainable growth David Berman, Head of R&D Delivering on our promise Bahija Jallal, CEO Q&A Session 3 4Q23 & FY23 financial results Brian Di Donato, CFO … of 8% Collaboration revenues 2.2 2.6 10.7 R&D expense 43.2 45.6 163.5 SG&A expenses 35.5 41.4 144.5 Net income/(loss) for the period 0.9 (19.7) (55.3
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
, as we continued our commercialization efforts.
For the fourth quarter and year ended December 31, 2023, our research and development (R&D) expenses were … and associated staff costs, increases related to consumables and facilities costs, and decreased R&D tax credits due to us no longer qualifying
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
forward and utilization against future operating profits.
As a company that carries out extensive research and development, or R&D, activities, we … benefit from the U.K. R&D tax relief programs, historically being the Small and Medium-sized Enterprises R&D tax relief program, or SME Program
8-K
x4d jzlokojn0yrx4za
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
6-K
EX-99.2
q20ecjm2rjk
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
8icl5p u6w
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
zjumt538wcu
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
jelmt
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
3nt3p
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
0zmlz65kq00n
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
ydq3l25ric
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
ezipqlostgxf7
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
8x9li5v2f4ins6el
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.4
ta3ryy2 rwc9oy3zqgd4
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
lcuoktvtd
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
da3v1ni
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
03xm16iid6nrc7 j8
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am